Fosamax and Osteonecrosis of the Jaw: Risk and Causation – What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context: General Health and Science Information

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic options. Within this broad framework, discussions of bone health and osteoporosis management have historically emphasized the benefits of bisphosphonate therapies, such as Fosamax, in reducing fracture risk. This heritage provides a baseline for interpreting how established treatments are later scrutinized for rare but serious adverse events. Transitioning from this general health perspective to a more focused occupational exposure concern requires a shift in analytical lens. In mass production environments, the handling of pharmaceutical compounds introduces distinct risk profiles that differ from patient-level therapeutic use. Workers involved in the manufacturing, packaging, or quality control of bisphosphonate medications may encounter concentrated forms of these substances through inhalation or dermal contact. This occupational context raises questions about cumulative exposure thresholds and potential biological effects that are not addressed by standard clinical studies designed for prescribed doses. The pivot from general health information to occupational exposure thus centers on the difference between controlled therapeutic administration and uncontrolled industrial contact. While patient-focused literature examines dose-response relationships for prescribed regimens, the manufacturing setting demands evaluation of airborne particulates, surface contamination, and repeated low-level exposure. This transition reframes the inquiry from “what risk does a patient face” to “what risk does a worker face,” preserving a neutral academic tone while shifting the domain of concern.

Bridge Transition: From General Health to Occupational Exposure

Building on the legacy context, this article now focuses specifically on the known adverse effects of Fosamax (alendronate), particularly osteonecrosis of the jaw (ONJ), and examines the evidence from clinical studies and prescribing information. While the primary data derive from patient populations, the mechanistic insights and risk factors are relevant for understanding potential occupational hazards. The following sections detail the medical evidence linking Fosamax to ONJ, including incidence, risk factors, and mechanistic pathways, providing a foundation for assessing both therapeutic and occupational exposure scenarios.

Medical Evidence: Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone in the mandible or maxilla. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or infection. The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Bisphosphonates accumulate in bone and suppress osteoclast activity, which may impair bone remodeling and healing, particularly in the jaw where there is high bone turnover and frequent microtrauma from dental procedures. This suppression can lead to avascular necrosis when combined with local factors such as infection or dental surgery.

Risk Factors and Incidence of ONJ in Fosamax Users

Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in osteoporosis patients is low. A cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). This study underscores that while the relative risk increases with longer exposure, the absolute risk remains small.

Adequacy of Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4 "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined and recommends considering drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings provide clinicians with information to assess risk and counsel patients. For causation-related considerations, affected patients should be aware that ONJ is a recognized but rare adverse effect of Fosamax. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk is higher with longer duration of use and in the presence of other risk factors such as dental procedures or cancer therapies. Patients who develop ONJ should discontinue Fosamax if severe symptoms develop, and most experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the decision to discontinue should be made in consultation with a healthcare provider, weighing the benefits of osteoporosis treatment against the risk of ONJ. In summary, studies show that Fosamax is associated with an increased risk of ONJ, particularly with longer exposure and in the presence of dental procedures or other risk factors. The absolute risk remains low, but the relative risk increases with duration of use. The prescribing information provides warnings and recommendations for risk management, including consideration of drug discontinuation after 3-5 years for low-risk patients and before invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax (alendronate), a bisphosphonate, can increase the risk of ONJ by suppressing bone remodeling. The prescribing information includes a specific warning about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in patients taking Fosamax for osteoporosis?

ONJ is rare in osteoporosis patients. A cohort study found absolute risk approximately 0.05% after 5 years, though relative risk increases with longer use (eightfold after 10 years) (https://pubmed.ncbi.nlm.nih.gov/39400702).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.